0


Developing New Ways To Reduce Prescription Drug Abuse

author: admin1 5:00 am EST July 19, 2013
By Jeremy MorrisAssociate Editor, USDR

   

The Center for Lawful Access and Abuse Deterrence (CLAAD) praised Signature Therapeutics, Inc. today for taking a national lead in biopharmaceutical research and development to reduce prescription drug abuse. Signature Therapeutics is a privately held company developing next-generation abuse-deterrent prescription medications.

   

Drug abuse is a major public health problem that impacts society on multiple levels. Directly or indirectly, society in general is affected by drug abuse. Drug abuse not only affects those who are addicted but family members and loved ones who are connected to the addict. Family members of anyone with drug abuse issues also go through major negative changes as a result of having someone they love who cannot stop using drugs. Oftentimes family members will feel helpless as to what to do to help their loved one to recover from drug abuse and addiction. Drug rehab programs have been helped those struggling with addiction problems successfully over the years. Click here for more rehab information.

   

More than 2.7 percent of the U.S. population currently abuses prescription drugs.[1] In 2010, prescription drug overdoses took the lives of 22,134 Americans.[2] Since 2009, CLAAD has called for private-sector research into novel technologies to reduce prescription drug abuse.

   

Michael Barnes, executive director of CLAAD, said, "Signature Therapeutics has distinguished itself in a growing market for safer medications by thinking big."

   

Signature Therapeutics is creating novel innovations, including "prodrugs," which would resist common methods of drug abuse, such as melting and injecting, crushing and snorting, or chewing before swallowing.  The company's pills are designed to be bioactivated, meaning that when taken by mouth, enzymes in the gastrointestinal tract trigger the release of the active ingredient.  Administered in any other way, a pill would not produce euphoria or any other significant effect.

   

Signature Therapeutics intends to apply its prodrug technology beyond opioids to other classes of commonly abused medications that lack safety features, such as stimulants used to treat attention-deficit disorder. Opioid pain relievers are the most commonly abused prescription drugs, but the abuse of tranquilizers, stimulants, and sedatives is also harmful and prevalent.[3]  In 2011, the anti-anxiety medication alprazolam was the most commonly found drug in overdose cases in Georgia, according to an analysis of autopsies.[4]  A study at the University of Kentucky found that out of 1,811 undergraduates, 34 percent reported improper use of stimulants.[5]

   

"Signature Therapeutics is the only company that I am aware of that is developing abuse-deterrent medications in a variety of drug classes," Barnes said. Wes Sterman, CEO of Signature Therapeutics, said, "We are thrilled that CLAAD has recognized our commitment to raising the bar for abuse resistance."

   

The opinions expressed in the columns written by US Daily Review's writers only reflect the opinion
of the individual writer. If you disagree with something, we invite you to engage our writers and carry
on a thoughtful dialogue.

Leave a Reply

*

Commnet

EcoPlus is powered by PlusCaptcha.



Get educated about retirement
You'll thank yourself later.

Open and fund an IRA today
+get upto $600. >
replay
More Stories Updated  

Jul 30, 2014 . 0  Comment

by Candace Salima, Senior Contributor at US Daily Review I was asked an interesting question this week: “Candace, why do you fight so hard for

Read More...

Jul 30, 2014 . 0  Comment

By USDR 2014’s Best States for Teen Drivers 2014’s Worst States for Teen Drivers 1 New York 41 Arizona 2 Hawaii T-42 Missouri 3 Illinois

Read More...

Jul 30, 2014 . 0  Comment

By Joe Messina Special for USDR         President Obama is our perfect president. He makes no mistakes and no bad decisions. Just

Read More...

Jul 30, 2014 . 0  Comment

By USDR     Rep. Kevin Brady, Chairman of the congressional Joint Economic Committee responded to today’s report by the Bureau of Economic Analysis (BEA)

Read More...